Aseptic Processing: A Vision of the Future

July 2nd 2025

Drug Solutions Podcast: Growth and Advancements in Fill/Finish

The company is voluntarily recalling one lot of cefazolin for injection, USP, 1 gram per vial due to customer complaints of the wrong product being included in a carton.

Felicity Thomas

June 25th 2024

Hikma Pharmaceuticals Invests $1 Billion to Expand US Generic Drug Capabilities, Releases Sustainability Report

In this episode, Hanns-Christian Mahler from ten23 Health chats about the advances in fill/finish.

June 30th 2025

Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines

The company is expanding its US manufacturing and R&D capabilities with a $1 billion investment by 2030.

Feliza Mirasol

April 30th 2024

Prokaryotics Licenses Gram-Negative Antibiotic Potentiator from Northern Antibiotics

In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.

Close up the media plate on hand medical technicians working on bacterial culture and drug resistance of pathogens in laboratory. | Image Credit: © analysis121980 - stock.adobe.com

Priothera Awarded €1.7M in Innovation Contest for Hematologic Malignancy Treatments

Prokaryotics will gain worldwide rights to develop, manufacture, and commercialize NAB741, a non-bioactive polymyxin designed to increase permeability of the outer membrane of Gram-negative bacteria.

3D Rendering of CAR - Chimeric Antigen Receptor Between T-Cell and Cancer Cell | Image Credit: © Alpha Tauri 3D - stock.adobe.com

Sandoz Recalls Cefazolin Due to Mispackaging, Opens Biosimilar Facility in Slovenia

The company’s mocravimod, a novel oral S1P receptor, is being evaluated for its efficacy as an addition to CAR-T cell therapies.

Related Content

July 2nd 2025

Drug Solutions Podcast: Growth and Advancements in Fill/Finish

The company is voluntarily recalling one lot of cefazolin for injection, USP, 1 gram per vial due to customer complaints of the wrong product being included in a carton.

Felicity Thomas

June 25th 2024

Hikma Pharmaceuticals Invests $1 Billion to Expand US Generic Drug Capabilities, Releases Sustainability Report

In this episode, Hanns-Christian Mahler from ten23 Health chats about the advances in fill/finish.

June 30th 2025

Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines

The company is expanding its US manufacturing and R&D capabilities with a $1 billion investment by 2030.

Feliza Mirasol

April 30th 2024

Prokaryotics Licenses Gram-Negative Antibiotic Potentiator from Northern Antibiotics

Priothera Awarded €1.7M in Innovation Contest for Hematologic Malignancy Treatments

Prokaryotics will gain worldwide rights to develop, manufacture, and commercialize NAB741, a non-bioactive polymyxin designed to increase permeability of the outer membrane of Gram-negative bacteria.